UCB SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.56 USD | -0.13% |
|
+1.19% | +59.54% |
| 11/04 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
| 11/04 | UCB : Berenberg, Buy, raises its price target | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With an expected P/E ratio at 61.13 and 28.38 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 4.62 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +59.54% | 26.41B | - | ||
| -1.64% | 90.28B | A- | ||
| -0.66% | 39.5B | A- | ||
| -15.83% | 31.71B | B- | ||
| -21.68% | 14.34B | C | ||
| -8.73% | 12.89B | B- | ||
| -10.32% | 11.8B | D+ | ||
| -45.77% | 10.95B | B | ||
| +3.30% | 8.85B | B+ | ||
| +92.69% | 7.41B | D |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- UCB Stock
- UCBJY Stock
- Ratings UCB SA
